These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical characteristics and disease course before and after SARS-CoV-2 infection in a large cohort of systemic sclerosis patients. Güler AA; Özçimen B; Aydoğdu MS; Sari A; Numune A; Ersan NT; Çolak S; Karadeniz H; Vasi İ; Küçük H; Yalçinkaya Y; Erden A; Kayaalp M; Öztürk MA; Göker B; Omma A; Yilmaz S; Koca SS; Inanç M; Akdoğan A; Tufan A Turk J Med Sci; 2024; 54(1):76-85. PubMed ID: 38812619 [TBL] [Abstract][Full Text] [Related]
5. The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Orlandi M; Lepri G; Bruni C; Wang Y; Bartoloni A; Zammarchi L; Cometi L; Guiducci S; Matucci-Cerinic M; Bellando-Randone S Clin Rheumatol; 2020 Jul; 39(7):2043-2047. PubMed ID: 32514674 [TBL] [Abstract][Full Text] [Related]
6. Case Report: Systemic Sclerosis After Covid-19 Infection. Fineschi S Front Immunol; 2021; 12():686699. PubMed ID: 34262566 [TBL] [Abstract][Full Text] [Related]
7. Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma. Chong WH; Saha BK; Beegle S Am J Med Sci; 2023 Feb; 365(2):198-204. PubMed ID: 35276077 [TBL] [Abstract][Full Text] [Related]
9. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database. Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080 [TBL] [Abstract][Full Text] [Related]
10. Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study. Wangkaew S; Euathrongchit J; Wattanawittawas P; Kasitanon N; Louthrenoo W Mod Rheumatol; 2016 Jul; 26(4):588-93. PubMed ID: 26561397 [TBL] [Abstract][Full Text] [Related]
11. Interstitial lung disease in South Africans with systemic sclerosis. Ashmore P; Tikly M; Wong M; Ickinger C Rheumatol Int; 2018 Apr; 38(4):657-662. PubMed ID: 29185086 [TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330 [TBL] [Abstract][Full Text] [Related]
13. [Interstitial lung disease in systemic sclerosis]. Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D Rev Mal Respir; 2007 Oct; 24(8):1035-46. PubMed ID: 18033190 [TBL] [Abstract][Full Text] [Related]
14. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G; Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380 [TBL] [Abstract][Full Text] [Related]
15. Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. Hoa S; Bernatsky S; Steele RJ; Baron M; Hudson M; Rheumatology (Oxford); 2020 May; 59(5):1108-1117. PubMed ID: 31535689 [TBL] [Abstract][Full Text] [Related]
16. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis]. Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432 [TBL] [Abstract][Full Text] [Related]
17. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341 [TBL] [Abstract][Full Text] [Related]
18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study. Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796 [TBL] [Abstract][Full Text] [Related]
19. Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study. Vandecasteele E; Melsens K; Vanhaecke A; Blockmans D; Bonroy C; Carton C; Deschepper E; De Keyser F; Houssiau F; Piette Y; Vanthuyne M; Verbeke K; Westhovens R; Wuyts WA; De Langhe E; Brusselle G; Smith V Semin Arthritis Rheum; 2021 Oct; 51(5):969-976. PubMed ID: 34403812 [TBL] [Abstract][Full Text] [Related]
20. [Interstitial lung disease in systemic sclerosis]. Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D Presse Med; 2006 Dec; 35(12 Pt 2):1943-51. PubMed ID: 17159721 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]